ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

Is Site Of Back Pain Related To Location Of Inflammatory and Structural Lesions On MRI In Patients With Chronic Back Pain?

Manouk de Hooge1, Rosaline van den Berg2, Floris van Gaalen2, Victoria Navarro-Compán2, Monique Reijnierse3, Karen Fagerli4, Maureen C. Turina5, Maikel van Oosterhout6, Roberta Ramonda7, Tom Huizinga2 and Désirée van der Heijde1, 1Leiden University Medical Center, Leiden, Netherlands, 2Rheumatology, Leiden University Medical Center, Leiden, Netherlands, 3Radiology, Leiden University Medical Center, Leiden, Netherlands, 4Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, 5Department of Clinical Immunology and Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6Rheumatology, GHZ Hospital, Gouda, Netherlands, 7Rheumatology Unit, University of Padova, Padova, Italy

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Back pain and spondylarthritis, MRI

  • Tweet
  • Email
  • Print
Session Information

Title: Spondylarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment: Therapeutics and Outcomes in Spondyloarthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: Pain has found to be related to inflammatory lesions in thoracic, lumbar and sacroiliac joints (SIJ) sites and to structural lesions in the SIJ site in the DESIR cohort. Our aim was to evaluate if localisation of back pain, as indicated by patients, is related to location of BME lesions seen on MRI (in spine (MRI-spine) or sacroiliac joints (SIJ) (MRI-SI)) in patients with chronic back pain.

Methods: Chronic back pain patients (≥3 months, ≤2 years, onset <45 years) recruited from 5 participating centres were included in the SPondyloArthritis Caught Early (SPACE)-cohort. Pain was indicated by patients at different sites (thoracic, lumbar, buttock, total spine). Patients underwent MRI-spine and MRI-SI. On MRI-spine anterior/posterior BME and fatty lesions suggestive of spondylitis were scored when visible on ≥2 consecutive slices. For any other structural lesion (erosions or syndesmophytes), suggestive of spondylitis, presence on ≥ 1 slice was sufficient. On MRI-SI, BME, fatty lesions, sclerosis and erosions, suggestive of spondylitis, were scored when ≥1 lesion was present on ≥2 consecutive slices or >1 lesion on 1 slice. Presence of ankylosis on ≥1 slice was scored. MRIs were scored independently by 3 blinded, well calibrated readers. Agreement of 2/3 readers was used. Association between pain site and BME location was assessed by logistic regression analysis adjusted for gender, HLA-B27 and age at onset of back pain resulting in adjusted Odds Ratios (OR).

Results: In 296 patients, data of the location of pain, MRI-spine (n=293) and MRI-SI (n=288) was available. Mean age at pain onset was 28.9 years, 35.1% male, 38.5% HLA-B27+ and 41.9% fulfilled the ASAS axSpA classification criteria. The prevalence of pain and lesions is shown in the table. The ORs of pain and MRI lesions at same site for the different patient group are shown in the table. Pain in the thoracic site was significantly associated with BME lesions at the same site in the whole patient group. Similar ORs were found in the no-SpA and axSpA subgroups, though not significant due to the lower amount of patients. Pain was significantly associated with fatty and any structural lesions in the buttock/SIJ site in the axSpA supgroup (see table).

Conclusion: The localisation of pain in the spine (thoracic, lumbar, buttock or total spine), as indicated by the patient, is significantly related to the location of BME lesions in thoracic site in patients with chronic back pain. In addition, in the subgroup with axSpA patients there is a significant relation between buttock pain and any structural lesions seen on MRI-SI.

Reference: 1Blachier M. ARD 2013 Jun;72(6):979-985 Aug 14

Prevalence of pain and lesions

 

Back pain

BME lesions

Fatty lesions

Any structural lesion

Cervical

ND

5 (1.7%)

9 (3%)

16 (5.4%)

Thoracic

108 (36.5%)

52 (17.6%)

45 (15.2%)

80 (27%)

Lumbar

244 (82.4%)

65 (22%)

33 (11.1%)

59 (19.9%)

Buttock/SIJ

100 (33.8%)

67 (22.6%)

36 (12.2%)

49 (14.2%)

Total spine

10 (3.4%)

0

4 (1.4%)

 8 (2.7%)

Any site in the spine

296 (100%)

95 (32.1%)

60 (25%)

101 (34.1%)

Odds ratios of pain at the same site

 

OR (CI) all patients (n=296)

OR (CI) axSpA patients (n=124)

OR (CI) no-SpA patients (n=172)

BME lesions

 

 

 

Thoracic site

2.07 (1.08–3.95;p<0.03)

2.11 (0.87–5.15)

2.54 (0.91–7.05)

Lumbar site

1.39 (0.65–3.11)

1.26 (0.47–3.40)

1.75 (0.37–8.35)

Buttock/SIJ site

0.63 (0.34–1.16)

0.55 (0.23–1.28)

0.27 (0.06–1.28)

Fatty lesions

 

 

 

Thoracic site

1.10 (0.54–2.24)

1.23 (0.49–3.06)

1.13 (0.35–3.62)

Lumbar site

0.62 (0.26–1.51)

0.76 (0.23–2.44)

0.38 (0.92–1.60)

Buttock/SIJ site

1.06 (0.49–2.30)

3.71 (1.15–11.96; p<0.03)

0.57 (0.25–1.28)

Any structural lesion

 

 

 

Thoracic site

1.23 (0.71–2.14)

1.20 (0.53–2.70)

1.49 (0.67–3.32)

Lumbar site

0.99 (0.47–2.15)

0.74 (0.27–2.01)

1.08 (0.29–4.07)

Buttock/SIJ site

1.62 (0.95–2.78)

5.10 (1.45–17.92; p<0.01)

0.56 (0.25–1.27)


Disclosure:

M. de Hooge,
None;

R. van den Berg,
None;

F. van Gaalen,
None;

V. Navarro-Compán,
None;

M. Reijnierse,
None;

K. Fagerli,
None;

M. C. Turina,
None;

M. van Oosterhout,
None;

R. Ramonda,
None;

T. Huizinga,
None;

D. van der Heijde,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/is-site-of-back-pain-related-to-location-of-inflammatory-and-structural-lesions-on-mri-in-patients-with-chronic-back-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology